Monoclonal Antibody
Manufacturing
Our team of experts has years of experience producing mAb therapies for both commercial and clinical projects.
Monoclonal Antibody Production
We have focused on expanding our capacity and capabilities to account for this important treatment type. With a large range of scales and capabilities for monoclonal development and manufacturing, we provide mAb services across Europe, N. America and Asia.
Our royalty-free, in-house cell line development system and mAb-focused downstream purification systems, allow us to shorten timelines and significantly reduce costs.
We offer perfusion and fed-batch capabilities and manufacturing scales from 500 L up to large-scale commercial manufacturing in stainless steel tanks of 20,000 L (17,000 working volume).
Got a project? Let's talk.Let us know how to reach you and what information we can provide.
Pioneering Accelerated mAb Manufacturing
Our proprietary mAb platform that gets you to market faster with guaranteed GMP quantities.
Fixed cost. Fast timelines. No surprises.
Our Antibody Expertise
With 30 years of scientific expertise, we've developed over 150 products, including 6 commercial successes, covering various cell types from monoclonal antibodies to fusion proteins. Our flexible processes cater to your needs, from method to molecule, and our scalable technology can handle up to 20,000 L, adapting to different manufacturing requirements. With CHEF1™, our proprietary expression platform, we offer accelerated CLD, providing clone selection in 4 months and 11 months to IND/GMP for specific mAbs.
Common Antibody Types
The most requested mAb types are predominantly IgG1 or IgG4. At AGC Biologics, IgG1 is the most commonly manufactured type due to our expertise with this antibody. IgG1 mAb has been developed to target specific antigens, making them valuable tools in the treatment of various diseases, including cancer and autoimmune disorders. We also have experience with the IgG4 mAb, which has been investigated for its potential in treating allergic diseases, autoimmune disorders, and certain types of cancer.
Other antibodies we have experience with include: IgM, IgE, IgD, IgA
10x More Productive Protein A Characterization!
Together in partnership with Gore, the R&D teams at AGC Biologics have taken new characterization technology, combined with single-use bioreactors, to produce a fully single-use process for monoclonal antibodies, dramatically reducing contamination risk.
Your End-to-End ADC Solution
Access the expertise of three world-class industry leaders, including AGC Biologics, that together can streamline your antibody drug conjugate projects. The Proveo™ partnership offers a risk-free timeline compression from DNA to fill & finish, ensuring your ADC project meet's your deadlines.
New market opportunities for pathogen-targeting monoclonal antibody (mAb) therapies
Download this white paper to learn more about how mAb therapies are changing the market and creating greater future opportunities for pathogen-focused mAb treatments.
Access PaperFill out the form to access "Monoclonals Revolutionizing Pathogen Treatments"
Monoclonal Antibody Development
Cell Line Development
We offer seamless process transfer to cGMP manufacturing, shorter timelines, and the ability to meet finite budgets.
Expert Knowledge
Our team's commercial track record and regulatory expertise bring speed and confidence to any mAb project.
Process Development
We are experts in tailoring our services to meet our customers' needs from pre-clinic to late-stage.
Analytical Development
Established robust in-house analytical methods utilizing state-of-the-art techniques to guarantee accurate and reliable characterization.